Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483027 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL18840312 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL31741256 | 1.00 | L3MBTL1 (0.35) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL6466868 | 0.94 | MAPK1 (0.39) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL10689947 | 0.94 | MAPK1 (0.39) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL12633006 | 0.94 | MAPK1 (0.39) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL8141964 | 0.94 | MAPK1 (0.39) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL16791667 | 0.82 | L3MBTL1 (0.35) | L3MBTL1MAPK1NPSR1 | |
| SCHEMBL20924286 | 0.78 | — | — | |
| SCHEMBL15481103 | 0.77 | L3MBTL1 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2755957-B1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2016-11-02 | — | — | EP | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8853418-B2 | Cyclopentylpyrazoles as N-type calcium channel blockers | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-20140051660-A1 | CYCLOPENTYLPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-20 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013092900-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013037942-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | L3MBTL1 1399/4885MAPK1 4670/4885NPSR1 1891/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | L3MBTL1 1228/4885MAPK1 4707/4885NPSR1 1486/4885 |
| US-20140051660-A1 | CYCLOPENTYLPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1A, CACNA1B, CACNA1E | L3MBTL1 2447/4885MAPK1 3510/4885NPSR1 215/4885 |
| US-20170233734-A1 | NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, ABHD16A, CETP | L3MBTL1 1098/4885MAPK1 4044/4885NPSR1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.